<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01250496</url>
  </required_header>
  <id_info>
    <org_study_id>ASSUAGETrial</org_study_id>
    <nct_id>NCT01250496</nct_id>
  </id_info>
  <brief_title>Attenuation of the Side Effect Profile of Regadenoson: Study With Aminophylline in Patients Undergoing Myocardial Perfusion Imaging</brief_title>
  <acronym>ASSUAGE</acronym>
  <official_title>Attenuation of the Side Effect Profile of Regadenoson: A Randomized Double-Blind Placebo Controlled Study With Aminophylline in Patients Undergoing Myocardial Perfusion Imaging.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rush University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rush University Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The routine administration of 75 mg of intravenous aminophylline following regadenoson
      (Lexiscan®), a commonly used medication for nuclear stress testing of the heart, can reduce
      the gastrointestinal (diarrhea and stomach upset) and other side effects related to
      regadenoson.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Approximately 250 patients who are referred for a nuclear stress testing of the heart with
      regadenoson (Lexiscan®) will be recruited to participate in the study. Following regadenoson
      (administered as part of a stress routine test protocol) participants will receive either
      aminophylline (75 mg - intravenously) or a matching inactive placebo (sterile salt water)
      injection. Participants will be surveyed for gastrointestinal symptoms and other side effects
      related to regadenoson. The frequency and severity of such side effects will be compared
      between the two study groups (aminophylline vs. placebo).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2010</start_date>
  <completion_date type="Actual">September 2011</completion_date>
  <primary_completion_date type="Actual">September 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Composite endpoints of abdominal cramps and diarrhea.</measure>
    <time_frame>within 2 hours from the intervention.</time_frame>
    <description>Patients will be surveyed for these symptoms following to the completion of the cardiac stress testing procedure and prior to discharge from the laboratory.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Global symptomatic burden of regadenoson</measure>
    <time_frame>within 2 hours from the intervention.</time_frame>
    <description>Secondary end-point encompasses the sum of all regadenoson-related adverse-events of flushing, feeling hot, chest pain, chest discomfort, angina, headache, dizziness, abdominal cramps or discomfort, diarrhea, nausea, bronchospasm and the need to administer a clinically indicated aminophylline to treat suspected regadenoson related side effects.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">248</enrollment>
  <condition>Patients Being Assessed With Nuclear Stress Testing of the Heart Using the Stress Agent Regadenoson (Lexiscan ®).</condition>
  <arm_group>
    <arm_group_label>Aminophylline</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>75 mg of intravenous aminophylline.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching normal saline placebo (sterile salt water).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aminophylline</intervention_name>
    <description>75 mg of intravenous aminophylline</description>
    <arm_group_label>Aminophylline</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching 0.9 Normal Saline (sterile salt water)administered intravenously.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult patients referred to undergo a clinically-indicated regadenoson-stress
             myocardial perfusion imaging at Rush University Medical Center

        Exclusion Criteria:

          -  Patient refusal to participate

          -  Known allergic reaction to aminophylline.

          -  Pre-existing headache or acute/subacute GI illness with symptoms of diarrhea,
             abdominal discomfort, nausea or vomiting.

          -  Any contraindication to aminophylline: hypotension, unstable cardiac arrhythmias and
             acute coronary symptoms.

          -  Uncontrolled seizure disorder defined as more than 2 seizure episodes in the past 12
             months or any seizure in the past week.

          -  Pregnant or breast-feeding women.

          -  Patients receiving anti-platelet agent dipyridamole (Persantine® or Aggrenox®).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Rush University Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Doukky R, Morales Demori R, Jain S, Kiriakos R, Mwansa V, Calvin JE. Attenuation of the side effect profile of regadenoson: a randomized double-blinded placebo-controlled study with aminophylline in patients undergoing myocardial perfusion imaging. &quot;The ASSUAGE trial&quot;. J Nucl Cardiol. 2012 Jun;19(3):448-57. doi: 10.1007/s12350-012-9533-x. Epub 2012 Mar 7.</citation>
    <PMID>22395779</PMID>
  </results_reference>
  <verification_date>November 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 29, 2010</study_first_submitted>
  <study_first_submitted_qc>November 29, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 30, 2010</study_first_posted>
  <last_update_submitted>November 27, 2012</last_update_submitted>
  <last_update_submitted_qc>November 27, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 28, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Rush University Medical Center</investigator_affiliation>
    <investigator_full_name>Rami Doukky</investigator_full_name>
    <investigator_title>Director of Nuclear Cardiology and Stress Testing Laboratories</investigator_title>
  </responsible_party>
  <keyword>regadenoson</keyword>
  <keyword>lexiscan</keyword>
  <keyword>aminophylline</keyword>
  <keyword>SPECT</keyword>
  <keyword>Myocardial Perfusion Imaging</keyword>
  <keyword>pharmacologic stress test</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Regadenoson</mesh_term>
    <mesh_term>Aminophylline</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>November 29, 2012</submitted>
    <returned>December 31, 2012</returned>
    <submitted>January 4, 2013</submitted>
    <returned>February 12, 2013</returned>
    <submitted>May 21, 2013</submitted>
    <submission_canceled>Unknown</submission_canceled>
    <submitted>June 21, 2013</submitted>
    <returned>July 30, 2013</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

